CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 139 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,434,265 | +48.3% | 552,598 | -10.1% | 0.00% | +50.0% |
Q2 2023 | $11,079,525 | +32.6% | 614,846 | +18.2% | 0.00% | 0.0% |
Q1 2023 | $8,354,379 | +242.4% | 520,198 | +290.2% | 0.00% | +100.0% |
Q4 2022 | $2,439,683 | +1.3% | 133,316 | +8.7% | 0.00% | 0.0% |
Q3 2022 | $2,409,000 | +32.6% | 122,668 | +25.9% | 0.00% | – |
Q2 2022 | $1,817,000 | -25.2% | 97,453 | -11.9% | 0.00% | -100.0% |
Q1 2022 | $2,428,000 | +38.9% | 110,603 | +79.8% | 0.00% | – |
Q4 2021 | $1,748,000 | +49.8% | 61,520 | +11.0% | 0.00% | – |
Q3 2021 | $1,167,000 | +1.7% | 55,425 | -8.8% | 0.00% | – |
Q2 2021 | $1,147,000 | -38.7% | 60,805 | -50.3% | 0.00% | – |
Q1 2021 | $1,870,000 | +3.4% | 122,352 | -4.5% | 0.00% | – |
Q4 2020 | $1,809,000 | +13.8% | 128,182 | +26.4% | 0.00% | – |
Q3 2020 | $1,589,000 | +545.9% | 101,392 | +622.0% | 0.00% | – |
Q2 2020 | $246,000 | -77.5% | 14,043 | -80.7% | 0.00% | – |
Q3 2019 | $1,093,000 | -75.8% | 72,640 | -59.9% | 0.00% | -100.0% |
Q2 2019 | $4,525,000 | +1279.6% | 180,990 | +1157.7% | 0.00% | – |
Q1 2019 | $328,000 | -0.3% | 14,391 | +31.1% | 0.00% | – |
Q4 2018 | $329,000 | – | 10,974 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 3,375,169 | $76,819,000 | 7.66% |
RA Capital Management | 1,875,209 | $42,680,000 | 1.84% |
Perceptive Advisors | 2,587,953 | $58,901,000 | 1.66% |
EMORY UNIVERSITY | 97,035 | $2,209,000 | 1.55% |
New Leaf Venture Partners, L.L.C. | 167,700 | $3,817,000 | 1.05% |
Orbimed Advisors | 1,914,282 | $43,569,000 | 0.67% |
Opaleye Management Inc. | 73,000 | $1,661,000 | 0.46% |
Novo Holdings A/S | 135,009 | $3,073,000 | 0.46% |
Virtus ETF Advisers LLC | 7,934 | $181,000 | 0.38% |
Eventide Asset Management | 384,000 | $8,740,000 | 0.30% |